Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly ...

Deutsche Bank analyst James Shin raised the firm’s price target on Gilead (GILD) to $135 from $120 and keeps a Buy rating on the shares.Elevate Your Investing Strategy: Take advantage of TipRanks ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...

Amid the questions about the Yeztugo rollout, Gilead’s second quarter performance offered some reassurance about the ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

A wave of factory closures is reshaping regional economies, displacing skilled laborers and weakening supply chains.

An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

Why an HIV patient advocacy group is suing the Trump administration over a Biden administration legal settlement with Gilead ...